Business Standard

Dr Reddy's Labs gains 3% on successful USFDA audit of Srikakulum plant

The stock of the pharmaceutical company was up 3% at Rs 2,546, trading higher for the sixth straight day, gaining 6% from Rs 2,407 on November 9, as compared to 1% rise in the S&P BSE Sensex.

Dr Reddy's
Premium

SI Reporter Mumbai
Shares of Dr. Reddy’s Laboratories were up 3% at Rs 2,546 per share on BSE in intra-day trade as  United States Food and Drug Administration (USFDA) has completed the audit of Andhra Pradesh plant with zero observations.

“The audit of our Formulations Srikakulum Plant (SEZ) Unit II, Andhra Pradesh by the USFDA, has been completed today with zero observations,” Dr. Reddy’s Laboratories said on Friday after market hours.

The stock of the pharmaceutical company was trading higher for the sixth straight day, up 6% from Rs 2,407 per share on November 9, as compared to 1% rise in the

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in